Clinical significance of tryptophan catabolism in follicular lymphoma

被引:7
|
作者
Masaki, Ayako [1 ,2 ]
Ishida, Takashi [1 ,3 ]
Maeda, Yasuhiro [4 ]
Ito, Asahi [1 ]
Suzuki, Susumu [5 ]
Narita, Tomoko [1 ]
Kinoshita, Shiori [1 ]
Yoshida, Takashi [1 ]
Ri, Masaki [1 ]
Kusumoto, Shigeru [1 ]
Komatsu, Hirokazu [1 ]
Inagaki, Hiroshi [2 ]
Ueda, Ryuzo [5 ]
Choi, Ilseung [6 ]
Suehiro, Youko [6 ]
Iida, Shinsuke [1 ]
机构
[1] Nagoya City Univ, Grad Sch Med Sci, Dept Hematol & Oncol, Nagoya, Aichi, Japan
[2] Nagoya City Univ, Grad Sch Med Sci, Dept Pathol & Mol Diagnost, Nagoya, Aichi, Japan
[3] Nagoya Univ, Grad Sch Med, Dept Immunol, Nagoya, Aichi, Japan
[4] Fujita Hlth Univ, Ctr Joint Res Facil Support, Toyoake, Aichi, Japan
[5] Aichi Med Univ, Sch Med, Dept Tumor Immunol, Nagakute, Aichi, Japan
[6] Kyushu Natl Canc Ctr, Dept Hematol, Fukuoka, Japan
关键词
follicular lymphoma; IDO; kynurenine; microenvironment; tryptophan; T-CELL PROLIFERATION; INDOLEAMINE 2,3-DIOXYGENASE; TUMOR MICROENVIRONMENT; GENE-EXPRESSION; SERUM; CANCER; INHIBITION; RITUXIMAB; MACROPHAGES; PROGNOSIS;
D O I
10.1002/hon.2804
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The enzyme, indoleamine 2,3-dioxygenase 1 (IDO), catabolizes tryptophan (Trp) in the kynurenine (Kyn) pathway, and is important in suppressing antitumor immune responses in the tumor microenvironment. With regard to previously untreated patients with follicular lymphoma (FL), we sought to establish the prognostic significance of Trp catabolism in this disease. Serum Trp and Kyn levels in 110 patients with FL were quantified, and their relationship to different clinical parameters studied. IDO expression in the lymph nodes of affected patients was studied. Study participants included 54 males and 56 females (age range 39-86, median 62 years), showing a 5-year overall survival (OS) rate of 78.5%. Patients with a high Kyn level (5-year OS, 65.0% vs. 81.7%;p = 0.026), high Kyn/Trp ratio (71.1% vs. 81.7%;p = 0.002), and low hemoglobin (Hb) level (p = 0.001; a component of FL international prognostic indexes) demonstrated a significantly shorter OS. Multivariate analysis included the following 10 variables: age, sex, serum beta 2-microglobulin, Hb, longest diameter of the largest involved node, Ann Arbor stage, serum lactate dehydrogenase, histologic grading, B symptoms, and serum Kyn/Trp ratio; a lower Hb level and a high Kyn/Trp ratio (HR, 3.239; 95% CI, 1.296-8.096) led to a significantly inferior OS. In the microenvironment, some CD11c-positive myeloid dendritic cells but not FL tumor cells were found to produce IDO. Overall, measuring levels of serum Kyn and Trp in individual patients with FL contributed to predicting their prognosis.
引用
收藏
页码:742 / 753
页数:12
相关论文
共 50 条
  • [1] Clinical significance of tryptophan catabolism in Hodgkin lymphoma
    Masaki, Ayako
    Ishida, Takashi
    Maeda, Yasuhiro
    Ito, Asahi
    Suzuki, Susumu
    Narita, Tomoko
    Kinoshita, Shiori
    Takino, Hisashi
    Yoshida, Takashi
    Ri, Masaki
    Kusumoto, Shigeru
    Komatsu, Hirokazu
    Inagaki, Hiroshi
    Ueda, Ryuzo
    Choi, Ilseung
    Suehiro, Youko
    Iida, Shinsuke
    CANCER SCIENCE, 2018, 109 (01) : 74 - 83
  • [2] Prognostic Significance of Tryptophan Catabolism in Adult T-cell Leukemia/Lymphoma
    Masaki, Ayako
    Ishida, Takashi
    Maeda, Yasuhiro
    Suzuki, Susumu
    Ito, Asahi
    Takino, Hisashi
    Ogura, Hiroka
    Totani, Haruhito
    Yoshida, Takashi
    Kinoshita, Shiori
    Narita, Tomoko
    Ri, Masaki
    Kusumoto, Shigeru
    Inagaki, Atsushi
    Komatsu, Hirokazu
    Niimi, Akio
    Ueda, Ryuzo
    Utsunomiya, Atae
    Inagaki, Hiroshi
    Iida, Shinsuke
    CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2830 - 2839
  • [3] Implications of the tumor microenvironment on survival and disease response in follicular lymphoma
    Gribben, John G.
    CURRENT OPINION IN ONCOLOGY, 2010, 22 (05) : 424 - 430
  • [4] Clinical significance of follicular lymphoma with monocytoid B cells
    Nathwani, BN
    Anderson, JR
    Armitage, JO
    Cavalli, F
    Diebold, J
    Drachenberg, MR
    Harris, NL
    Maclennan, KA
    Müller-Hermelink, HK
    Ullrich, FA
    Weisenburger, DD
    HUMAN PATHOLOGY, 1999, 30 (03) : 263 - 268
  • [5] Clinical significance of soluble form of poliovirus receptor in newly diagnosed follicular lymphoma
    Nabih, Nermeen A.
    Kamal, Amany M.
    Naguib, Mary G.
    EGYPTIAN JOURNAL OF HAEMATOLOGY, 2021, 46 (02) : 116 - 122
  • [6] Incidence and clinical significance of Bcl-2/IgH rearrangements in follicular lymphoma
    Montoto, S
    López-Guillermo, A
    Colomer, D
    Esteve, J
    Bosch, F
    Ferrer, A
    Villamor, N
    Moreno, C
    Campo, E
    Montserrat, E
    LEUKEMIA & LYMPHOMA, 2003, 44 (01) : 71 - 76
  • [7] Pathogenesis of follicular lymphoma
    Lackraj, Tracy
    Goswami, Rashmi
    Kridel, Robert
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (01) : 2 - 14
  • [8] Tumor Microenvironment and Microvascular Density in Follicular Lymphoma
    Tamma, Roberto
    Ingravallo, Giuseppe
    Annese, Tiziana
    Gaudio, Francesco
    Perrone, Tommasina
    Musto, Pellegrino
    Specchia, Giorgina
    Ribatti, Domenico
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (05)
  • [9] Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors
    Mozas, Pablo
    Lopez, Cristina
    Grau, Marta
    Nadeu, Ferran
    Clot, Guillem
    Valle, Sara
    Kulis, Marta
    Navarro, Alba
    Ramis-Zaldivar, Joan Enric
    Gonzalez-Farre, Blanca
    Rivas-Delgado, Alfredo
    Rivero, Andrea
    Frigola, Gerard
    Balague, Olga
    Gine, Eva
    Delgado, Julio
    Villamor, Neus
    Matutes, Estella
    Magnano, Laura
    Garcia-Sanz, Ramon
    Huet, Sarah
    Russell, Robert B.
    Campo, Elias
    Lopez-Guillermo, Armando
    Bea, Silvia
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (04) : 631 - 643
  • [10] Gene expression profiling in follicular lymphoma and its implication for clinical practice
    Janikova, Andrea
    Tichy, Boris
    Supikova, Jana
    Stano-Kozubik, Katerina
    Pospisilova, Sarka
    Kren, Leos
    Vasova, Ingrid
    Salek, David
    Mayer, Jiri
    LEUKEMIA & LYMPHOMA, 2011, 52 (01) : 59 - 68